🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting in excess of 82 million infections per year. Especially elevated rates are observed in the African continent and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The global health body has classified it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

One new antibiotic, marketed under the name a brand name, was cleared by the American regulatory agency in recent days for combating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that specific application of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against UTIs, was shown in trials to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment emerged from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Research Study Data and Global Access

As per data published in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This places it at an equal footing with the existing first-line therapy, which uses an injection and a pill. The study enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced optimism. Having a easy-to-administer therapy of this kind is hailed as a "critical tool" for public health efforts. This is considered essential to lessen the impact of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.